CO2018006126A2 - Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadas - Google Patents
Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadasInfo
- Publication number
- CO2018006126A2 CO2018006126A2 CONC2018/0006126A CO2018006126A CO2018006126A2 CO 2018006126 A2 CO2018006126 A2 CO 2018006126A2 CO 2018006126 A CO2018006126 A CO 2018006126A CO 2018006126 A2 CO2018006126 A2 CO 2018006126A2
- Authority
- CO
- Colombia
- Prior art keywords
- kidney disease
- polycystic kidney
- biomarker
- related applications
- rpe
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 abstract 2
- 102100032859 Protein AMBP Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257089P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062075 WO2017087409A1 (en) | 2015-11-18 | 2016-11-15 | Biomarker of polycystic kidney disease and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018006126A2 true CO2018006126A2 (es) | 2018-07-10 |
Family
ID=57539614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0006126A CO2018006126A2 (es) | 2015-11-18 | 2018-06-15 | Biomarcador de enfermedad poliquística renal y usos del mismo referencia cruzada a solicitudes relacionadas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11116755B2 (enExample) |
| EP (1) | EP3377908B1 (enExample) |
| JP (1) | JP6895963B2 (enExample) |
| KR (1) | KR20180083902A (enExample) |
| CN (1) | CN108700594B (enExample) |
| AU (1) | AU2016357720A1 (enExample) |
| BR (1) | BR112018009879A2 (enExample) |
| CO (1) | CO2018006126A2 (enExample) |
| EA (1) | EA201891170A1 (enExample) |
| MX (1) | MX2018006250A (enExample) |
| WO (1) | WO2017087409A1 (enExample) |
| ZA (1) | ZA201803035B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6895963B2 (ja) | 2015-11-18 | 2021-06-30 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
| US12527776B2 (en) * | 2019-02-04 | 2026-01-20 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
| JPWO2023145898A1 (enExample) * | 2022-01-27 | 2023-08-03 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710227B1 (en) | 1998-09-16 | 2004-03-23 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
| US6703395B2 (en) | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
| AU778735B2 (en) | 1998-06-16 | 2004-12-16 | Centre National De La Recherche Scientifique | Fused azepinone cyclin dependent kinase inhibitors |
| US6559152B2 (en) | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| ATE402257T1 (de) | 1999-05-24 | 2008-08-15 | Avi Biopharma Inc | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US6593356B2 (en) | 1999-10-20 | 2003-07-15 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| EP1278749B1 (en) | 2000-04-25 | 2005-01-26 | Bristol-Myers Squibb Company | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| WO2002022133A1 (en) | 2000-09-12 | 2002-03-21 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
| CA2432417A1 (fr) | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2003063764A2 (en) | 2001-07-10 | 2003-08-07 | Bristol-Myers Squibb Pharma Company | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7084271B2 (en) | 2002-09-04 | 2006-08-01 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2497544C (en) | 2002-09-04 | 2010-11-02 | Schering Corporation | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
| MXPA05002570A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CN1310918C (zh) | 2002-09-04 | 2007-04-18 | 先灵公司 | 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶 |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60317529T2 (de) | 2002-09-19 | 2008-09-25 | Schering Corp. | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| WO2004026872A1 (en) | 2002-09-19 | 2004-04-01 | Schering Corporation | Pyrazolopyridines as cyclin dependent kinase inhibitors |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| DE60317353T2 (de) | 2002-09-23 | 2008-08-28 | Schering Corp. | Imidazopyrazine als cdk-inhibitoren |
| AU2003275031B2 (en) | 2002-09-23 | 2006-08-17 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| CA2574709A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| EP2160478B1 (en) | 2007-06-06 | 2014-08-27 | Siemens Healthcare Diagnostics Inc. | Predictive diagnostics for kidney disease |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| WO2010141862A2 (en) | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102858985A (zh) * | 2009-07-24 | 2013-01-02 | 西格马-奥尔德里奇有限责任公司 | 基因组编辑方法 |
| CN102018702B (zh) | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| SG10201407881WA (en) | 2009-11-27 | 2015-01-29 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| WO2011084548A2 (en) | 2009-12-15 | 2011-07-14 | King Faisal Specialist Hospital & Research Centre | Methods and compositions for detecting recesssive familial fsgs and uses thereof |
| ES2606140T3 (es) | 2010-10-01 | 2017-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| JP6021021B2 (ja) | 2010-11-05 | 2016-11-02 | 国立大学法人京都大学 | 多発性嚢胞腎の検査方法および治療剤のスクリーニング方法 |
| SG10201602144PA (en) | 2011-10-03 | 2016-04-28 | Celmatix Inc | Methods and devices for assessing risk to a putative offspring of developing a condition |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| CN102590491B (zh) * | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿系统疾病的检测试剂盒、检测方法及其用途 |
| US10478446B2 (en) | 2012-07-03 | 2019-11-19 | Fondazione Centro San Raffaele Office Of Biotechnology Transfer | Compounds for use in polycystic kidney disease |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| RU2017106891A (ru) | 2014-08-04 | 2018-09-06 | Джензим Корпорейшн | Биомаркеры поликистозной болезни почек и пути их применения |
| JP6895963B2 (ja) | 2015-11-18 | 2021-06-30 | ジェンザイム・コーポレーション | 多発性嚢胞腎のバイオマーカーおよびその使用 |
-
2016
- 2016-11-15 JP JP2018525768A patent/JP6895963B2/ja active Active
- 2016-11-15 BR BR112018009879A patent/BR112018009879A2/pt not_active Application Discontinuation
- 2016-11-15 KR KR1020187016766A patent/KR20180083902A/ko not_active Withdrawn
- 2016-11-15 MX MX2018006250A patent/MX2018006250A/es unknown
- 2016-11-15 CN CN201680079045.XA patent/CN108700594B/zh active Active
- 2016-11-15 AU AU2016357720A patent/AU2016357720A1/en not_active Abandoned
- 2016-11-15 US US15/775,736 patent/US11116755B2/en active Active
- 2016-11-15 WO PCT/US2016/062075 patent/WO2017087409A1/en not_active Ceased
- 2016-11-15 EA EA201891170A patent/EA201891170A1/ru unknown
- 2016-11-15 EP EP16809582.6A patent/EP3377908B1/en active Active
-
2018
- 2018-05-09 ZA ZA2018/03035A patent/ZA201803035B/en unknown
- 2018-06-15 CO CONC2018/0006126A patent/CO2018006126A2/es unknown
-
2021
- 2021-08-17 US US17/404,701 patent/US12150938B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108700594B (zh) | 2021-06-29 |
| JP2019502902A (ja) | 2019-01-31 |
| MX2018006250A (es) | 2018-09-05 |
| US20180338961A1 (en) | 2018-11-29 |
| EP3377908A1 (en) | 2018-09-26 |
| AU2016357720A1 (en) | 2018-07-05 |
| US20210379031A1 (en) | 2021-12-09 |
| US11116755B2 (en) | 2021-09-14 |
| US12150938B2 (en) | 2024-11-26 |
| EA201891170A1 (ru) | 2018-11-30 |
| ZA201803035B (en) | 2019-02-27 |
| KR20180083902A (ko) | 2018-07-23 |
| BR112018009879A2 (pt) | 2018-11-13 |
| JP6895963B2 (ja) | 2021-06-30 |
| CN108700594A (zh) | 2018-10-23 |
| EP3377908B1 (en) | 2020-08-05 |
| WO2017087409A1 (en) | 2017-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| EP3571535A4 (en) | EYEPIECE FOR VIRTUAL, AUGMENTED OR MIXED REALITY SYSTEMS | |
| UA117364C2 (uk) | Похідні аматоксину | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| MX395149B (es) | Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer. | |
| BR112017002703A2 (pt) | anticorpos específicos de mmp9. | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| EA201890082A1 (ru) | Эпитоп антитела | |
| MX2017016253A (es) | Anticuerpos para cd40. | |
| BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
| CY1122233T1 (el) | Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο | |
| GT201800034A (es) | Anticuerpos anti-cd154 y métodos de uso de estos | |
| MX2017003387A (es) | Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico. | |
| MX2018006250A (es) | Biomarcador de enfermedad poliquistica renal y usos del mismo. | |
| MX2024011859A (es) | Biomarcadores de arn para angioedema hereditario | |
| CO2019006234A2 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal | |
| MX2018002354A (es) | Métodos para el tratamiento de una enfermedad poliquística renal. | |
| MX2021003298A (es) | Métodos para revertir la actividad ticagrelor. | |
| MX381948B (es) | Composiciones y metodos para determinar el pronostico de cancer de endometrio. |